Status:
COMPLETED
Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars
Lead Sponsor:
Innovative Medical
Conditions:
Scars
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.
Eligibility Criteria
Inclusion
- Female or male patients at least 18 years of age
- Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
- Able and willing to provide informed consent and likely to complete all study visits
- All Fitzpatrick skin types will be evaluated
Exclusion
- Known contraindications to Dermatix or any of its components
- Age of scar is \> 4 months
- Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00450775
Start Date
March 1 2007
End Date
March 1 2008
Last Update
September 25 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dadeland Dermatology
Coral Gables, Florida, United States, 33134